sjogren病的未来治疗

Raphaèle Seror, Gaetane Nocturne, Xavier Mariette
{"title":"sjogren病的未来治疗","authors":"Raphaèle Seror,&nbsp;Gaetane Nocturne,&nbsp;Xavier Mariette","doi":"10.1016/j.monrhu.2022.03.006","DOIUrl":null,"url":null,"abstract":"<div><p>Sjögren's disease is a systemic autoimmune disease characterized by a triad of symptoms affecting all patients (dryness, pain, and fatigue) and systemic involvement that can affect one-third of patients. The management of patients has long suffered from the lack of effective treatments. However, knowledge of the epidemiology, classification criteria, assessment of systemic activity (ESSDAI) and patient criteria (ESSPRI) has progressed over the last decade. Similarly, advances in the understanding of the pathogenesis of the disease have led to a more targeted therapeutic approach. In this review, we will summarize the advances that have been made in outcome assessment that will shape future trials. We will also provide an overview of promising drugs being evaluated in Sjögren's disease.</p></div>","PeriodicalId":101125,"journal":{"name":"Revue du Rhumatisme Monographies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Traitements futurs de la maladie de Sjögren\",\"authors\":\"Raphaèle Seror,&nbsp;Gaetane Nocturne,&nbsp;Xavier Mariette\",\"doi\":\"10.1016/j.monrhu.2022.03.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Sjögren's disease is a systemic autoimmune disease characterized by a triad of symptoms affecting all patients (dryness, pain, and fatigue) and systemic involvement that can affect one-third of patients. The management of patients has long suffered from the lack of effective treatments. However, knowledge of the epidemiology, classification criteria, assessment of systemic activity (ESSDAI) and patient criteria (ESSPRI) has progressed over the last decade. Similarly, advances in the understanding of the pathogenesis of the disease have led to a more targeted therapeutic approach. In this review, we will summarize the advances that have been made in outcome assessment that will shape future trials. We will also provide an overview of promising drugs being evaluated in Sjögren's disease.</p></div>\",\"PeriodicalId\":101125,\"journal\":{\"name\":\"Revue du Rhumatisme Monographies\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue du Rhumatisme Monographies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1878622722000479\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue du Rhumatisme Monographies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878622722000479","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

Sjögren's病是一种全身性自身免疫性疾病,其特点是所有患者都有三种症状(干燥、疼痛和疲劳),三分之一的患者都有全身累及。长期以来,对患者的管理一直缺乏有效的治疗方法。然而,关于流行病学、分类标准、系统活动评估(ESSDAI)和患者标准(ESSPRI)的知识在过去十年中取得了进展。同样,对疾病发病机制的理解的进步导致了更有针对性的治疗方法。在这篇综述中,我们将总结在结果评估方面取得的进展,这些进展将影响未来的试验。我们还将概述正在对Sjögren疾病进行评估的有前途的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Traitements futurs de la maladie de Sjögren

Sjögren's disease is a systemic autoimmune disease characterized by a triad of symptoms affecting all patients (dryness, pain, and fatigue) and systemic involvement that can affect one-third of patients. The management of patients has long suffered from the lack of effective treatments. However, knowledge of the epidemiology, classification criteria, assessment of systemic activity (ESSDAI) and patient criteria (ESSPRI) has progressed over the last decade. Similarly, advances in the understanding of the pathogenesis of the disease have led to a more targeted therapeutic approach. In this review, we will summarize the advances that have been made in outcome assessment that will shape future trials. We will also provide an overview of promising drugs being evaluated in Sjögren's disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信